Form 4 Filing for Vaxcyte, Inc.

Jim Wassil, EVP, Chief Scientific Officer, and COO of Vaxcyte, Inc. (PCVX), reported a series of transactions on October 5, 2026. Wassil acquired 18,000 shares of Common Stock at a price of $5.35 per share, increasing his post-transaction holdings to 163,435 shares. Concurrently, he disposed of 18,000 shares of Common Stock at $86.74 per share, reducing his holdings to 145,435 shares. These transactions were executed under a Rule 10b5-1 trading plan. Additionally, Wassil exercised a stock option to acquire 18,000 shares of Common Stock at an exercise price of $5.35 per share, resulting in 46,398 shares held following the transaction. The stock option is fully vested and exercisable, with an expiration date of April 17, 2030. All transactions were direct ownership.